YAP1 and cancer: High YAP/TAZ activity drives proliferation, invasion and metastases of cancer cells [4, 116–119], and is often associated with poor prognosis [120, 121], therapy resistance, including resistance to chemotherapeutic drugs [118, 121–125], radiation [124, 126] and molecularly targeted therapies [127, 128], and relapse [107] of cancers.